18.66
-0.1(-0.53%)
Currency In USD
| Previous Close | 18.76 |
| Open | 18.87 |
| Day High | 19.98 |
| Day Low | 18.59 |
| 52-Week High | 26.95 |
| 52-Week Low | 2.54 |
| Volume | 990,981 |
| Average Volume | 3.49M |
| Market Cap | 1.56B |
| PE | -34.56 |
| EPS | -0.54 |
| Moving Average 50 Days | 12.78 |
| Moving Average 200 Days | 7.36 |
| Change | -0.1 |
If you invested $1000 in Corvus Pharmaceuticals, Inc. (CRVS) since IPO date, it would be worth $1,309.47 as of February 15, 2026 at a share price of $18.66. Whereas If you bought $1000 worth of Corvus Pharmaceuticals, Inc. (CRVS) shares 5 years ago, it would be worth $5,126.37 as of February 15, 2026 at a share price of $18.66.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
GlobeNewswire Inc.
Jan 23, 2026 10:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten public offering of 9,085,778 shares of it
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
GlobeNewswire Inc.
Jan 22, 2026 3:53 AM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 7,900,677 shares of it
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Jan 20, 2026 9:01 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of shares